Emergent Biosolutions Inc
Officers & Directors
Executives: - Joseph C. Papa President, Chief Executive Officer and Director (Principal Executive Officer) - Richard S. Lindahl Executive Vice President, Chief Financial Officer and Treasurer (Principal Financial and Accounting Officer) - Sean Kirk Executive Vice President and Chief Manufacturing Officer - Kathryn Zoon, Ph.D. Director Board of Directors: - Kathryn Zoon, Ph.D. Director - Louis W. Sullivan, M.D. Director - Marvin White Director - Neal Fowler Director - Don DeGolyer Director - Zsolt Harsanyi, Ph.D. Director - Keith Katkin Director - Sujata Dayal Director - Ronald B. Richard Director ,
Emergent Biosolutions Inc currently has 900 employees.
News about Emergent Biosolutions Inc Key Personnel |
In a pivotal moment for Emergent BioSolutions Inc. (NYSE:EBS), the company has finalized the sale of its Baltimore-Bayview drug substance manufacturing facility to Syngene International, a transaction valued at approximately $36.5 million. This sale, announced on March 19, 2025, marks a significant shift in Emergent’s operational strategy as it refocuses on its core competencies within the biopharmaceutical sector. The proceeds from this transaction, albeit subject to customary post-closing adjustments, introduce a much-needed influx of capital for the company at a time when it is grappling with broader market challenges.Earlier, on January 8, 2025, Emergent BioSolutions reported securing a $20 million con...
|
In a move reflecting its unwavering commitment to public health, Emergent BioSolutions Inc. (NYSE: EBS) has recently secured significant funding to bolster its national preparedness initiatives. On September 26, 2024, the company announced the execution of two contract options valued at $67.4 million to procure additional treatment courses of TEMBEXA (brincidofovir). This decision underscores the U.S. government s proactive measures against potential smallpox outbreaks, emphasizing the vital role of TEMBEXA in the treatment of human smallpox disease for both adult and pediatric patients, including neonates. The new procurements are part of a larger, existing 10-year contract with the Biomedical Advanced Rese...
|
Emergent BioSolutions Transfers Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals - A Strategic Move amid Changing Dynamics in the Pharmaceutical Industry
Emergent BioSolutions, a global specialty pharmaceutical company, has recently finalized the sale of its drug product facility in Baltimore-Camden to Bora Pharmaceuticals, an affiliate of Bora Pharmaceuticals Co., Ltd. This move comes amidst a rapidly evolving landscape in the pharmaceutical industry, as companies seek to realign their strategies to meet the demands of the future. The sale, valued at approximately $30 million, marks a significant strategic decision by Emergent BioSolutions to focus on its core competencies and streamline...
|
In a bid to revitalize its financial health and position itself for long-term success, Emergent BioSolutions Inc. has embarked on a multi-year transformation plan. The company, a leading player in the healthcare sector, has made significant strides in advancing its operational efficiency, reducing costs, and generating cash to increase profitability and alleviate its overall debt burden.
The firm s rigorous and disciplined approach towards implementing its operational strategy is resulting in a tangible improvement in Emergent s financial position. The company s recent achievements include robust cash generation and meaningful debt repayment, confirming its commitment to this transformation plan. As...
|
|
|
